Synthroid, Levoxyl Generics Clear FDA; Sandoz Has Broadest Line
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan receives the first ANDA approval for Abbott’s market-leading levothyroxine brand Synthroid. Sandoz, through a partnership with Mova, will market a levothyroxine tablet rated bioequivalent to both Synthroid and King’s Levoxyl. The approvals follow FDA’s decision to reject an Abbott citizen petition.